Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide levels in healthy men

We previously reported that the administration a miglitol after a meal was equally effective as administration before a meal Since glucaizon-like peptide-1 (GLP-1) reportedly promotes islet cell growth and inhibits apoptosis in animal models, an increase in GLP-1 secretion might also be beneficial for islet cell function and mass in humans Miglitol reportedly enhances GLP-1 responses and reduces glucose-dependent insulinotropic polypeptide (GIP) However, whether the effect of miglitol on these incretins is comparable when mightol is administered before or arm a meal remains uncertain Here, we compared the effects of the pre-meal versus post-meal administration of miglitol on the plasma active GLP-1 and total GIP levels in healthy men Mightol was administered according to three different intake schedules in each subject (control no drug, intake I drug administered just before a meal 150 mg], intake 2 drug administered at 30 min after the start of a meal [50 mg]) The area under the curve (AUC) of the plasma GLP-1 level for the intake 1 group was significantly greater than those of the control and intake 2 groups The AUCs of the plasma GIP level for the intake 1 and 2 groups were significantly smaller than that of the control The administration of miglitol just before a meal, rather than after a meal, is recommended in view of the up-regulation of GLP-1